Accueil › Gliome › New York › New York City
Essais cliniques pour Gliome à New York City, NY
25 études pour Gliome recherchent des participants dans et autour de New York City (dans un rayon d'environ 30 miles). Ouvrez une étude pour voir qui peut participer et comment contacter l'équipe.
Texte officiel de l'étude (anglais)
Vous recrutez pour une étude ? Mettez-la en avant en haut de cette page — $99 pour 30 jours →
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Recrutement en coursPhase 1/2
- Research Site, New York
- Research Site, New York
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
Recrutement en coursPhase 1/2
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Recrutement en coursPhase 2
- Columbia University Irving Medical Center, New York
A Study of Mirdametinib in People With Central Nervous System Tumors
Recrutement en coursPhase 1/2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Glioma Developmental and HyperActive Ras Tumor (DHART) Board
Recrutement en coursÉtude observationnelle
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Recrutement en coursPhase 3
- NYU Langone Health, New York
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University Medical Center, New York
- et 1 autres
Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
Recrutement en coursPhase 1
- New York University, New York
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
Recrutement en coursPhase 4
- New York Presbyterian Hospital-Columbia University Medical Center, New York
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma
Recrutement en coursPhase 1
- NYU Langone Health, New York
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Recrutement en coursPhase 2
- Columbia University Irving Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
Pembrolizumab, Olaparib, and Temozolomide for People With Glioma
Recrutement en coursPhase 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma
Recrutement en cours
- NYU Langone Health, New York
MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas
Recrutement en coursPhase 1/2
- Memorial Sloan Kettering Cancer Center, New York
Chronic CED of TPT for Recurrent Malignant Glioma
Recrutement en coursPhase 1
- Columbia University Irving Medical Center / NewYork-Presbyterian Hospital, New York
A Study of 177Lu-PSMA-617 in People With Gliomas
Recrutement en coursPhase 1
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
Recrutement en coursPhase 3
- Lenox Hill Brain Tumor Center, New York
Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma
Recrutement en cours
- Lenox Hill Brain Tumor Center, New York
Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)
Recrutement en cours
- Lenox Hill Brain Tumor Center, New York
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
Recrutement en coursPhase 1
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
- Columbia University Medical Center, New York
- Memorial Slone Kettering Cancer Center, New York
Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252
Recrutement en coursPhase 1
- Memorial Sloan Kettering, New York
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Recrutement en coursPhase 1/2
- NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
Recrutement en coursPhase 2
- Lenox Hill Brain Tumor Center, New York
FUS Etoposide for DMG
Recrutement en coursPhase 1
- Columbia University Irving Medical Center, New York
Concurrent XRD-0394 With Radiation Therapy for High Grade Gliomas
Recrutement en coursPhase 1 précoce
- NYU Langone Health, New York
Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
Recrutement en cours
- Memorial Sloan Kettering Cancer Center, New York
Essais pour Gliome dans d'autres villes
- Houston, TX23 études
- Boston, MA20 études
- Washington, DC19 études
- Philadelphia, PA16 études
- Columbus, OH15 études
- Miami, FL15 études
- San Francisco, CA14 études
- Chicago, IL13 études
- Durham, NC12 études
- Seattle, WA11 études
- St. Louis, MO10 études
- Aurora, CO10 études
Autres études à New York City
- Cancer du sein136 études
- Cancer du poumon non à petites cellules121 études
- Cancer (tous types)109 études
- Cancer de la prostate103 études
- Cancer métastatique93 études
- Cancer colorectal78 études
- Cancer de l'ovaire69 études
- Cancer du poumon60 études
- Myélome multiple60 études
- Cancer du pancréas60 études
- Cancer de l'endomètre52 études
- Leucémie aiguë myéloïde51 études
Source : ClinicalTrials.gov, données récupérées le 6 oct. 2026. Chaque étude définit ses propres critères d'éligibilité ; l'équipe de l'étude décide qui peut y participer.